Paul Chin

Paul Chin

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2012 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
RER. van Egmond
R. van Egmond
PCPaul Chin
Paul Chin
MZM. Zhang
M. Zhang
CSC. W. Sies
C. W. Sies
MBM. L. Barclay
M. L. Barclay
Summary: Background: Up to 20% of patients on thiopurine therapy fail to achieve adequate drug response. Many of these patients preferentially produce the toxic 6‐methylmercaptopurine metabolites (6‐MMP) rather than the active 6‐thioguanine nucleotides (6‐TGN) resulting in a high 6‐MMP/6‐TGN ratio (>20) and increased risk of hepatotoxicity.Aim: To determine the prevalence of preferential 6‐MMP producers and define the relationships between 6‐TGN, 6‐MMP and thiopurine methyltransferase (TPMT).Methods: The database of 6‐TGN, 6‐MMP and TPMT measurements from patients throughout New Zealand was used to calculate patients’ 6‐MMP/6‐TGN ratios and identify those with high (>20) or normal ratio (≤20).The TPMT enzyme activity was compared amongst the groups.Results: Of 1879 patients with TPMT, 6‐TGN and 6‐MMP results, 349 (19%) had a 6‐MMP/6‐TGN ratio >20. The mean TPMT enzyme activity was slightly lower for those with a 6‐MMP/6‐TGN ratio ≤20 vs. >20, which achieved statistical significance (12.2 vs. 13.2; P < 0.001). However, the distributions of TPMT enzyme activity were similar, with 97% of TPMT results falling between 5.0 and 17.6 IU/mL for both groups. In all, 17% of those with 6‐MMP/6‐TGN ratio ≤20 were intermediate TPMT metabolisers (TPMT 5.0–9.2 IU/mL) vs. 7% in those with a ratio >20.Conclusions: In this patient population with measured 6‐MMP/6‐TGN ratios, 19% of patients were preferential 6‐MMP producers. The results show that high TPMT enzyme activity is not the major reason for preferential 6‐MMP production in most patients with a high metabolite ratio. This suggests that there are one or more important alternative mechanisms for preferentially producing 6‐MMP.

6 May 2014 in Drugs in R&D
Verified
Journal Article
Open access
PDF file
PCPaul Chin
Paul Chin
Daniel F. B. WrightDaniel F. B. Wright
Daniel F. B. Wright
MZMei Zhang
Mei Zhang
MWMary C. Wallace
Mary C. Wallace
RRRebecca L. Roberts
Rebecca L. Roberts
EBEvan J. Begg
Evan J. Begg
Aims Dabigatran is largely cleared by renal excretion. Renal function is thus a major determinant of trough dabigatran concentrations, which correlate with the risk of thromboembolic and haemorrhagic outcomes. Current dabigatran dosing guidelines use the Cockcroft–Gault (CG) equation to gauge renal function, instead of contemporary equations including the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations employing creatinine (CKD-EPI_Cr), cystatin C (CKD-EPI_Cys) and both renal biomarkers (CKD-EPI_CrCys). Methods A linear regression model including the dabigatran etexilate maintenance dose rate, relevant interacting drugs and genetic polymorphisms (including CES1), was used to analyse the relationship between the values from each renal function equation and trough steady-state plasma dabigatran concentrations. Results The median dose-corrected trough steady-state plasma dabigatran concentration in 52 patients (38–94 years) taking dabigatran etexilate was 60 µg/L (range 9–279). The dose-corrected trough concentration in a patient on phenytoin and phenobarbitone was >3 standard deviations below the cohort mean. The CG, CKD-EPI_Cr, CKD-EPI_Cys and CKD-EPI_CrCys equations explained (R 2, 95 % CI) 32 % (9–55), 37 % (12–60), 41 % (16–64) and 47 % (20–69) of the variability in dabigatran concentrations between patients, respectively. One-way analysis of variance (ANOVA) comparing the R 2 values for each equation was not statistically significant (p = 0.74). Discussion Estimates of renal function using the four equations accounted for 32–47 % of the variability in dabigatran concentrations between patients. We are the first to provide evidence that co-administration of phenytoin/phenobarbitone with dabigatran etexilate is associated with significantly reduced dabigatran exposure.

9 October 2012 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
BJBerit Packert Jensen
Berit Packert Jensen
PCPaul Chin
Paul Chin
RRRebecca Lee Roberts
Rebecca Lee Roberts
EBEvan James Begg
Evan James Begg

1 February 2014 in Therapeutic Drug Monitoring
Verified
Journal Article
Closed access
PBPamela J. B Pharm Buffery
Pamela J. B Pharm Buffery
KAKirstie M. Msc Allen
Kirstie M. Msc Allen
PCPaul Chin
Paul Chin
GMGrant A. Bsc Moore
Grant A. Bsc Moore
MBMurray L. Barclay
Murray L. Barclay
EBEvan J. Begg
Evan J. Begg
Background: A busulfan concentration monitoring and dosing service has been provided by Christchurch Hospital since 1998. This study aimed to see (1) the percentage of patients with an area under the concentration time curve (AUC) outside the target range and had dose adjustment, (2) how busulfan clearance (CL) relates to body weight, and (3) if fewer samples could be used to predict doses. Methods: Blood samples were taken from patients after oral administration, usually at 0.5, 1, 1.5, and 6 hours, and after the start of a 2-hour intravenous (IV) infusion of busulfan, at 1, 2, 2.5, 3, 6, and 8 hours. Dose adjustment was made based on the AUC compared with the target range. The relationship of CL and body weight for the IV group was used to develop a revised IV dosing schedule. The bias and imprecision of AUCs estimated using fewer sampling points were examined to see if sampling could be economized. Results: Data were available for 150 patients but for 6 patients, data were incomplete and excluded. Of the remaining 144 patients (256 sample sets, 209 oral, 47 IV, 62% with repeats), 38% (IV) and 35% (oral) of patients had AUCs within the target range after the first dose. Dose adjustment was made in 47% and 34% of patients dosed IV and orally, respectively, after which there was a trend to more patients achieving the target AUC. A nonlinear relationship was found between CL and body weight. The initial IV dosing schedule was revised to take this into account. Sampling for busulfan concentration measurement at 3 points (2.5, 4, 8 hours) or 2 points (2.5, 8 hours) after the start of the infusion enabled accurate and precise estimates of AUC0–24. Conclusions: Around two thirds of patients treated with busulfan were outside the target AUC range after the first dose. Dose adjustment was made in 37% of patients. The relationship between CL and body weight was used to revise the initial IV dosing schedule. Sampling for AUC estimation could be reduced to 2 time points after IV dosing.


21 August 2014 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
PCPaul Chin
Paul Chin
Daniel F. B. WrightDaniel F. B. Wright
Daniel F. B. Wright
DPDavid M. Patterson
David M. Patterson
MDMatthew P. Doogue
Matthew P. Doogue
EBEvan J. Begg
Evan J. Begg